CIViC Evidence Items

4 evidence items indexed

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
A	DPYD	DPYD*2A HOMOZYGOSITY	Predictive	Supports	Adverse Response	Cancer	Capecitabine,Tegafur,Fluorouracil	Caudle et al., 2013
A	DPYD	DPYD*13 HOMOZYGOSITY	Predictive	Supports	Adverse Response	Cancer	Fluorouracil,Capecitabine,Tegafur	Caudle et al., 2013
A	DPYD	RS67376798 HOMOZYGOSITY	Predictive	Supports	Adverse Response	Cancer	Fluorouracil,Tegafur,Capecitabine	Caudle et al., 2013
C	DPYD	EXON 11-19 DELETION	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Fluorouracil,Leucovorin	Majounie et al., 2020